MCID: BRC012
MIFTS: 70

Brucellosis

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Brucellosis

MalaCards integrated aliases for Brucellosis:

Name: Brucellosis 12 77 54 60 56 3 45 15 17 74
Undulant Fever 12 54 3
Mediterranean Fever 12 77
Gibraltar Fever 12 54
Malta Fever 12 54
Bang's Disease 12
Maltese Fever 12
Cyprus Fever 54
Rock Fever 54

Characteristics:

Orphanet epidemiological data:

60
brucellosis
Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 60  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:11077
ICD9CM 36 023 023.9
MeSH 45 D002006
NCIt 51 C84602
SNOMED-CT 69 75702008
MESH via Orphanet 46 D002006
ICD10 via Orphanet 35 A23.0 A23.1 A23.2 more
UMLS via Orphanet 75 C0006309
Orphanet 60 ORPHA1304
UMLS 74 C0006309

Summaries for Brucellosis

NIH Rare Diseases : 54 Brucellosis is a bacterial infection that spreads from animals to people via unpasteurized dairy products or by exposure to contaminated animal products or infected animals. Animals that are most commonly infected include sheep, cattle, goats, pigs, and dogs. Brucellosis can cause of range of signs and symptoms, some of which may persist or recur. Initial symptoms may include fever, sweats, malaise, anorexia, headache, fatigue, and/or pain in the muscles, joints, and/or back. Symptoms that may persist or recur include fevers, arthritis, swelling of the testicle and scrotum, swelling of the heart (endocarditis), neurologic symptoms (in up to 5% of cases), chronic fatigue, depression, and/or swelling of the liver or spleen. People who are in jobs or settings that increase exposure to the bacteria are at increased risk for infection. Antibiotics are used to treat brucellosis. Recovery may take a few weeks to several months, and relapses are common. Death from brucellosis is rare, occurring in no more than 2% of cases.

MalaCards based summary : Brucellosis, also known as undulant fever, is related to amyloidosis aa and purpura, and has symptoms including fever, fatigue and back pain. An important gene associated with Brucellosis is MEFV (MEFV Innate Immuity Regulator, Pyrin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Tacrolimus and Abatacept have been mentioned in the context of this disorder. Affiliated tissues include testes, heart and breast, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A primary bacterial infectious disease that is caused by the bacteria of the genus Brucella, when humans come in contact with contaminated animals or animal products or ingestion of infected food products. The disease has symptom fever, has symptom sweat, has symptom headache, has symptom back pain, has symptom physical weakness, has symptom joint pain and has symptom fatigue.

Wikipedia : 77 Brucellosis is a highly contagious zoonosis caused by ingestion of unpasteurized milk or undercooked... more...

Related Diseases for Brucellosis

Diseases related to Brucellosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 699)
# Related Disease Score Top Affiliating Genes
1 amyloidosis aa 32.0 CRP MEFV SAA1
2 purpura 30.7 CRP IL6 TNF
3 crohn's disease 30.6 CRP IL10 SLC11A1 TNF
4 polyarteritis nodosa 30.6 CRP IL6 MEFV
5 end stage renal failure 30.6 CRP IL6 TNF
6 q fever 30.5 IFNG IL10 IL4 IL6 TLR4 TNF
7 ige responsiveness, atopic 30.5 IFNG IL10 IL4
8 proliferative glomerulonephritis 30.4 IFNG IL4 IL6
9 relapsing polychondritis 30.4 CRP IFNG IL6
10 leptospirosis 30.4 CRP CXCL8 IFNG IL10 IL6 TNF
11 endocarditis 30.3 CRP CXCL8 IL10 IL6 TNF
12 vasculitis 30.3 CRP MEFV TNF
13 cryopyrin-associated periodic syndrome 30.3 CRP IL1RN IL6
14 drug reaction with eosinophilia and systemic symptoms 30.2 CRP TNF
15 neuritis 30.2 IFNG IL4 TNF
16 scleritis 30.2 IFNG IL4 TNF
17 campylobacteriosis 30.2 IFNG SLC11A1 TLR4
18 hyper-igd syndrome 30.1 CRP IL1RN SAA1
19 toxoplasmosis 30.1 IFNG IL10 IL4 IL6 TLR4 TNF
20 ischemic heart disease 30.1 CRP IL6 TNF
21 myelitis 30.1 IL17A IL6 TNF
22 severe acute respiratory syndrome 30.1 CRP CXCL8 IFNG TNF
23 atherosclerosis susceptibility 30.1 CRP IL6 TLR4 TNF
24 extrapulmonary tuberculosis 30.1 IFNG IL10 IL1RN SLC11A1
25 arteries, anomalies of 30.0 CRP IL6 TNF
26 capillary leak syndrome 30.0 CXCL8 IL2 IL6
27 crohn's colitis 30.0 CXCL8 IFNG IL2 TNF
28 mixed connective tissue disease 30.0 IFNG IL10 IL6 TNF
29 connective tissue disease 30.0 IFNG IL10 IL6 TNF
30 aseptic meningitis 30.0 CXCL8 IFNG IL10 IL1RN TNF
31 acute respiratory distress syndrome 30.0 CXCL8 IL6 TNF
32 tuberculous peritonitis 30.0 CRP IFNG TNF
33 hepatitis a 30.0 IFNG IL10 TNF
34 septic arthritis 30.0 CRP CXCL8 TLR4
35 heart disease 30.0 CRP CXCL8 IL10 IL6 TNF
36 bacteriuria 30.0 CXCL8 IL6 TLR4
37 spondyloarthropathy 29.9 IFNG IL10 IL17A IL4 IL6 TNF
38 infective endocarditis 29.9 CRP IL6 TNF
39 relapsing fever 29.9 CRP MEFV TNF
40 human immunodeficiency virus infectious disease 29.9 IFNG IL10 IL2 IL6 TNF
41 hashimoto thyroiditis 29.9 IFNG IL2RA IL4
42 salmonellosis 29.9 IFNG IL18 SLC11A1 TLR4
43 pustulosis of palm and sole 29.9 IL1RN TNF
44 meningitis 29.9 CRP CXCL8 IFNG IL10 IL6 TNF
45 rheumatic fever 29.9 IL10 IL2 IL6 TNF
46 myocardial infarction 29.9 CRP IL10 IL6 TLR4 TNF
47 spondylitis 29.9 CRP IL17A IL1RN IL6 TNF
48 acute pancreatitis 29.8 CRP CXCL8 IL10 IL18 IL6
49 poliomyelitis 29.8 IFNG IL10 IL4 TNF
50 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 29.8 IFNG IL10 IL17A

Graphical network of the top 20 diseases related to Brucellosis:



Diseases related to Brucellosis

Symptoms & Phenotypes for Brucellosis

Symptoms:

12
  • fever
  • fatigue
  • back pain
  • headache
  • joint pain
  • sweat
  • physical weakness

GenomeRNAi Phenotypes related to Brucellosis according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 CXCL8 IL10 IL17A IL18 IL2 IL2RA
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 CXCL8 IL10 IL17A IL18 IL2 IL2RA

MGI Mouse Phenotypes related to Brucellosis:

47 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.32 CRP IFNG IL10 IL17A IL18 IL1RN
2 hematopoietic system MP:0005397 10.31 IFNG IL10 IL17A IL18 IL1RN IL2
3 immune system MP:0005387 10.3 CRP IFNG IL10 IL17A IL18 IL1RN
4 growth/size/body region MP:0005378 10.29 IFNG IL10 IL17A IL18 IL1RN IL2
5 digestive/alimentary MP:0005381 10.28 IFNG IL10 IL17A IL18 IL2 IL2RA
6 cellular MP:0005384 10.25 IFNG IL10 IL18 IL1RN IL2 IL4
7 cardiovascular system MP:0005385 10.21 CRP IFNG IL10 IL18 IL1RN IL2
8 mortality/aging MP:0010768 10.18 IFNG IL10 IL17A IL18 IL1RN IL2
9 endocrine/exocrine gland MP:0005379 10.13 IFNG IL10 IL17A IL2 IL2RA IL4
10 integument MP:0010771 10.09 IFNG IL10 IL18 IL1RN IL4 IL6
11 liver/biliary system MP:0005370 10.01 IFNG IL10 IL2 IL4 IL6 MEFV
12 reproductive system MP:0005389 9.91 IFNG IL10 IL1RN IL2 IL4 IL6
13 neoplasm MP:0002006 9.87 IFNG IL10 IL2 IL6 SLC11A1 TLR4
14 respiratory system MP:0005388 9.81 IFNG IL10 IL17A IL2 IL2RA IL4
15 skeleton MP:0005390 9.61 IFNG IL10 IL17A IL1RN IL4 IL6
16 vision/eye MP:0005391 9.28 IFNG IL10 IL18 IL2 IL2RA IL4

Drugs & Therapeutics for Brucellosis

Drugs for Brucellosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 846)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 6473866 445643 439492
2
Abatacept Approved Phase 4 332348-12-6 10237
3
Mycophenolic acid Approved Phase 4 24280-93-1 446541
4
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
5
Atenolol Approved Phase 4,Not Applicable 29122-68-7 2249
6
Naloxone Approved, Vet_approved Phase 4,Not Applicable 465-65-6 5284596
7
Tocopherol Approved, Investigational Phase 4,Phase 2,Phase 3 1406-66-2 14986
8
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
9
Tenofovir Approved, Experimental, Investigational Phase 4,Phase 2 147127-20-6 464205
10
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
11
Cobicistat Approved Phase 4 1004316-88-4
12
Colchicine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-86-8 2833 6167
13
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 62-31-7, 51-61-6 681
14
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
15
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
16
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
17
Maraviroc Approved, Investigational Phase 4,Phase 2,Phase 3 376348-65-1 3002977
18
Daptomycin Approved, Investigational Phase 4 103060-53-3 16129629
19
Telavancin Approved Phase 4 372151-71-8
20
Ranolazine Approved, Investigational Phase 4 95635-55-5, 142387-99-3 56959
21
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
22
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
23
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
24
Regadenoson Approved, Investigational Phase 4,Not Applicable 313348-27-5 219024
25
Adenosine Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 58-61-7 60961
26
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 1 616-91-1 12035
27
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
28
Nicotine Approved Phase 4,Not Applicable 54-11-5 89594 942
29
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
30
Vancomycin Approved Phase 4,Phase 3 1404-90-6 14969 441141
31
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7440-66-6 32051
32
Norepinephrine Approved Phase 4,Phase 2 51-41-2 439260
33
Citalopram Approved Phase 4,Phase 3,Phase 2,Not Applicable 59729-33-8 2771
34
Donepezil Approved Phase 4 120014-06-4 3152
35
Memantine Approved, Investigational Phase 4 19982-08-2 4054
36
Febuxostat Approved Phase 4,Phase 2 144060-53-7 134018
37 Nutmeg Approved Phase 4
38
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
39
Amodiaquine Approved, Investigational Phase 4,Phase 3 86-42-0 2165
40
Artesunate Approved, Investigational Phase 4,Phase 3 88495-63-0 5464098 6917864
41
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
42
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
43
Dapsone Approved, Investigational Phase 4 80-08-0 2955
44
Naproxen Approved, Vet_approved Phase 4,Phase 2 22204-53-1 156391 1302
45
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
46
Ibuprofen Approved Phase 4,Not Applicable 15687-27-1 3672
47
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198
48
Ramipril Approved Phase 4 87333-19-5 5362129
49
Telmisartan Approved, Investigational Phase 4,Phase 3 144701-48-4 65999
50
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 2 93-14-1 3516

Interventional clinical trials:

(show top 50) (show all 1066)
# Name Status NCT ID Phase Drugs
1 VeinViewer Assisted Intravenous Catheter Placement in the Pediatric Emergency Department Unknown status NCT00468065 Phase 4
2 Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression Unknown status NCT01875224 Phase 4 Belatacept;Tacrolimus
3 Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina. Unknown status NCT01397994 Phase 4 Nicorandil;Atenolol
4 Injection Assistance Device Versus Manual Injections for Delivery of Dermal Fillers Unknown status NCT01492140 Phase 4
5 Nasal Naloxone for Narcotic Overdose Unknown status NCT01912573 Phase 4 Intranasal (IN) naloxone;Intravenous (IV) naloxone;Intramuscular (IM) naloxone;Intraosseus (IO) naloxone
6 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
7 A Prospective Study of the InterFuse T(tm), Unknown status NCT02678130 Phase 4
8 Sleep and Cognition After Atripla to Stribild Switch Unknown status NCT02283060 Phase 4 Stribild;Atripla
9 The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With FMF Completed NCT02602028 Phase 4 colchicine
10 A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac) Completed NCT01449006 Phase 4 Maraviroc
11 Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD) Completed NCT00663403 Phase 4 Daptomycin
12 Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation Completed NCT00578968 Phase 4 Tiotropium;Placebo
13 Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5 Completed NCT02392208 Phase 4 Telavancin
14 Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients Completed NCT01435174 Phase 4 Ranolazine
15 Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD) Completed NCT01048879 Phase 4
16 Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis Completed NCT00877370 Phase 4 ertapenem
17 The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems Completed NCT00988117 Phase 4 Rivastigmine Patch 9.5 cm2
18 Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET Completed NCT01109992 Phase 4 Exercise plus Regadenoson (Lexercise);Regadenoson (Lexiscan)
19 Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease Completed NCT02476526 Phase 4 Low Volume iso-osmolar non-ionic radio contrast medium;Acetylcysteine Inhalation;Sodium Bicarbonate Solution
20 Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS) Completed NCT00263393 Phase 4 ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin
21 Helping Those With Mental Illness Quit Smoking Completed NCT01783912 Phase 4 Nicotine Patch
22 Ankle Block Versus Popliteal Fossa Block as Primary Anesthesia for Forefoot Surgical Procedures Completed NCT01376960 Phase 4
23 ULTRA Study for Pacemaker Patients Completed NCT00133289 Phase 4
24 Effect of Age on Latanoprost 0.005% in Patients With Glaucoma Completed NCT00224289 Phase 4 Latanoprost 0.005%
25 Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas Completed NCT00295178 Phase 4 Daptomycin;Vancomycin
26 Chronic Insertional Achilles Tendonitis Treated With or Without Flexor Hallucis Longus Tendon Transfer Completed NCT00950053 Phase 4
27 Needle Length In Obese Insulin-Using Diabetic Subjects Completed NCT00541372 Phase 4
28 Antidepressant Medication Plus Donepezil for Treating Late-life Depression Completed NCT00177671 Phase 4 Escitalopram;Donepezil;Venlafaxine;Placebo;Duloxetine
29 World-wide Randomized Antibiotic Envelope Infection Prevention Trial Completed NCT02277990 Phase 4
30 Foot and Ankle Clinic Application for Liposomal Related Anesthetic Completed NCT02586077 Phase 4 Exparel
31 Comparative Performance of PureVision, Acuvue Oasys and O2Optix Completed NCT00640341 Phase 4
32 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
33 Safety and Acceptability of the PrePex™ Device for Male Circumcision in Zambia Completed NCT01844102 Phase 4
34 The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina Completed NCT01763996 Phase 4 Febuxostat;Febuxostat placebo
35 A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors Completed NCT02019264 Phase 4 APD356-Lorcaserin hydrochloride;Placebo
36 Study of Long-term Peg Intron vs. Colchicine in Non-responders. Completed NCT00179413 Phase 4 PEG -Intron;Colchicine
37 Restricting the Use of Artesunate Plus Amodiaquine Combination Therapy to Malaria Cases Confirmed by a Dipstick Test: A Cluster Randomised Control Trial Completed NCT00832754 Phase 4
38 Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression Completed NCT00531947 Phase 4 Selegiline Transdermal System;Placebo
39 Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo Completed NCT01308619 Phase 4 Doxycycline
40 Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency Completed NCT00243542 Phase 4 ACZONE Gel, 5%;Vehicle
41 Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen Completed NCT00346216 Phase 4 celecoxib;Ibuprofen;Naproxen
42 Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo. Completed NCT00153101 Phase 4 Telmisartan;Combination of Telmisartan and Ramipril;Ramipril
43 Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery Recruiting NCT03858231 Phase 4 Norco 5Mg-325Mg Tablet;Ibuprofen 600 mg;Acetaminophen 325Mg Tab
44 Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy Recruiting NCT03554486 Phase 4 Fiasp;Novolog
45 CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera Recruiting NCT03705585 Phase 4 Vivotif Typhoid Oral Vaccine;Vaxchora
46 A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis Recruiting NCT03573323 Phase 4 Ixekizumab;Guselkumab;Placebo
47 Randomised Evaluation of Sodium Dialysate Levels on Vascular Events Recruiting NCT02823821 Phase 4
48 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE ) Recruiting NCT03518034 Phase 4 Testosterone;Placebo
49 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
50 INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure Recruiting NCT02787044 Phase 4

Search NIH Clinical Center for Brucellosis

Cochrane evidence based reviews: brucellosis

Genetic Tests for Brucellosis

Anatomical Context for Brucellosis

MalaCards organs/tissues related to Brucellosis:

42
Testes, Heart, Breast, Prostate, Liver, Lung, Brain

Publications for Brucellosis

Articles related to Brucellosis:

(show top 50) (show all 3178)
# Title Authors Year
1
The Prevalence of Brucellosis in Different Provinces of Iran during 2013-2015. ( 30847321 )
2019
2
Multiple Myeloma or Brucellosis: ACase Report. ( 30848218 )
2019
3
Association of IL-17 gene polymorphisms and susceptibility to brucellosis in Hamadan, western Iran. ( 30851127 )
2019
4
Overexpression of wbkF gene in Brucella abortus RB51WboA leads to increased O-polysaccharide expression and enhanced vaccine efficacy against B. abortus 2308, B. melitensis 16M, and B. suis 1330 in a murine brucellosis model. ( 30856219 )
2019
5
Bayesian evaluation of three serological tests for the diagnosis of bovine brucellosis in Bangladesh. ( 30869026 )
2019
6
Seroprevalence of Human Brucellosis in Wadi Al Dawaser region of Saudi Arabia. ( 30881410 )
2019
7
Attenuated Salmonella secreting Brucella protective antigens confer dual-faceted protection against brucellosis and salmonellosis in a mouse model. ( 30885303 )
2019
8
Prevalence and Risk Factors of Brucellosis, Toxoplasmosis, and Neosporosis Among Yanbian Yellow Cattle in Jilin Province, China. ( 30328792 )
2019
9
Brucellosis seroprevalence in dairy cattle in China during 2008-2018: A systematic review and meta-analysis. ( 30308207 )
2019
10
EFFECTS OF BRUCELLOSIS SEROLOGIC STATUS ON PHYSIOLOGY AND BEHAVIOR OF ROCKY MOUNTAIN ELK ( CERVUS CANADENSIS NELSONI) IN SOUTHWESTERN MONTANA, USA. ( 30277828 )
2019
11
Risk factors of brucellosis (re-)incidence in sheep and goat flocks in an endemic area of Portugal. ( 30219999 )
2019
12
Analysis of domestic animal movements in Colombia (2006-2014) and their possible influence on the bovine brucellosis spread. ( 30209748 )
2019
13
Preventive factors related to brucellosis among rural population using the PRECEDE model: an application of path analysis. ( 30203266 )
2019
14
Prediction of the Omp16 Epitopes for the Development of an Epitope-based Vaccine Against Brucellosis. ( 29984663 )
2019
15
Brucellosis After Cardiac Transplantation. ( 29932889 )
2019
16
Epidemiological characteristics, clinical manifestations and laboratory findings in 850 patients with brucellosis in Heilongjiang Province, China. ( 31109292 )
2019
17
Comparison of six methods of DNA extraction for the diagnosis of bovine brucellosis by real-time PCR. ( 31101955 )
2019
18
Design and development of novel therapeutics for brucellosis treatment based on carbonic anhydrase inhibition. ( 31096856 )
2019
19
Economic and health burden of brucellosis in Kazakhstan. ( 31090193 )
2019
20
Time series analysis of human brucellosis in mainland China by using Elman and Jordan recurrent neural networks. ( 31088391 )
2019
21
An Evaluation of the National Brucellosis Surveillance System in Qatar, 2018. ( 31086754 )
2019
22
A headache with surprising outcome: first case of brucellosis caused by Brucella suis biovar 1 in Germany. ( 31073709 )
2019
23
Seropositivities against brucellosis, coxiellosis, and toxoplasmosis and associated factors in pregnant women with adverse pregnancy outcomes: A cross-sectional study. ( 31071166 )
2019
24
The influence of illness duration before diagnosis on clinical characteristics and outcome in human brucellosis. ( 31060447 )
2019
25
The use of CaSO4 drug delivery system in transforaminal lumbar interbody fusion for spinal brucellosis. ( 31054425 )
2019
26
Brucellosis awareness and knowledge in communities worldwide: A systematic review and meta-analysis of 79 observational studies. ( 31048848 )
2019
27
Spatial analysis to assess the relationship between human and bovine brucellosis in South Korea, 2005-2010. ( 31040303 )
2019
28
Brucellosis: A global concern. ( 31022022 )
2019
29
Brucellosis in pregnancy: results of multicenter ID-IRI study. ( 30989418 )
2019
30
FDG PET/CT of Spinal Brucellosis. ( 30985429 )
2019
31
Congenital brucellosis in a Chinese preterm neonate: A case report. ( 30971153 )
2019
32
Canine Brucellosis: Old Foe and Reemerging Scourge. ( 30961996 )
2019
33
Bovine brucellosis in Pakistan; an analysis of engagement with risk factors in smallholder farmer settings. ( 30957947 )
2019
34
Risk of adverse pregnancy outcomes and seroprevalence for brucellosis in pregnant women exposed to goats or raw goat products in southern Thailand: a prospective cohort study. ( 30953474 )
2019
35
Brucellosis Complicated by Kikuchi-Fujimoto Disease and Doxycycline-Induced Intracranial Hypertension. ( 30945234 )
2019
36
NOD-scid IL2rγnull Mouse Model is suitable to Study Osteoarticular Brucellosis and Vaccine Safety. ( 30936160 )
2019
37
A high-throughput screening for inhibitors of riboflavin synthase identifies novel antimicrobial compounds to treat brucellosis. ( 30927485 )
2019
38
Status and influencing factors of farmers' private investment in the prevention and control of sheep brucellosis in China: A cross-sectional study. ( 30908484 )
2019
39
Brucellosis after dengue. ( 30895885 )
2019
40
Risk factors for new bovine brucellosis infections in Colombian herds. ( 30845954 )
2019
41
Brucellosis knowledge, attitudes and practices of a South African communal cattle keeper group. ( 30843408 )
2019
42
Prevalence of caprine brucellosis on herds of toba communities in Villa Río Bermejito, Chaco, Argentina (October 2010). ( 30843366 )
2019
43
Emergency response to occupational brucellosis in a pharmaceutical manufacturing enterprise. ( 30839144 )
2019
44
Correction: Correction: Clinical features of 2041 human brucellosis cases in China. ( 30830949 )
2019
45
The impact of expanded brucellosis surveillance in beef cattle on human brucellosis in Korea: an interrupted time-series analysis. ( 30819243 )
2019
46
When brucellosis met the Assessment of SpondyloArthritis international Society classification criteria for spondyloarthritis: a comparative study. ( 30806857 )
2019
47
Neutrophils Dampen Adaptive Immunity in Brucellosis. ( 30804100 )
2019
48
Osteoarticular manifestations of human brucellosis: A review. ( 30788222 )
2019
49
Epidemiologic, clinical, and laboratory characteristics of childhood brucellosis : A study in an Iranian children's referral hospital. ( 30778882 )
2019
50
A review of the immunopathogenesis of Brucellosis. ( 30773082 )
2019

Variations for Brucellosis

Expression for Brucellosis

Search GEO for disease gene expression data for Brucellosis.

Pathways for Brucellosis

Pathways related to Brucellosis according to GeneCards Suite gene sharing:

(show top 50) (show all 82)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 CRP CXCL8 IFNG IL10 IL17A IL18
2
Show member pathways
13.87 CXCL8 IL10 IL17A IL18 IL2 IL2RA
3
Show member pathways
13.76 CXCL8 IFNG IL10 IL17A IL18 IL1RN
4
Show member pathways
13.65 CXCL8 IFNG IL10 IL17A IL18 IL2
5
Show member pathways
13.52 CXCL8 IL10 IL17A IL18 IL2 IL2RA
6
Show member pathways
13.44 CXCL8 IFNG IL10 IL17A IL18 IL1RN
7
Show member pathways
13.42 CXCL8 IL10 IL17A IL18 IL2 IL2RA
8
Show member pathways
13.22 IFNG IL2 IL2RA IL4 TLR4 TNF
9
Show member pathways
13.21 CXCL8 IFNG IL10 IL18 IL2 IL6
10
Show member pathways
13.05 IL2 IL2RA IL4 IL6 TLR4 TNF
11
Show member pathways
13.01 CXCL8 IFNG IL10 IL17A IL18 IL2
12 12.94 CXCL8 IFNG IL2 IL2RA IL4 IL6
13
Show member pathways
12.91 CXCL8 IFNG IL18 IL6 SAA1 TLR4
14
Show member pathways
12.82 IL2 IL2RA IL4 IL6 TNF
15
Show member pathways
12.78 IFNG IL10 IL18 IL2 IL2RA IL4
16
Show member pathways
12.74 IFNG IL10 IL17A IL18 IL2 IL6
17
Show member pathways
12.71 IFNG IL10 IL17A IL2 IL4 IL6
18 12.71 IFNG IL10 IL17A IL1RN IL2 IL2RA
19
Show member pathways
12.6 IFNG IL10 IL17A IL18 IL2 IL2RA
20
Show member pathways
12.55 IFNG IL10 IL2 IL2RA IL4 IL6
21
Show member pathways
12.53 IFNG IL2 IL4 TNF
22
Show member pathways
12.5 CXCL8 IFNG IL17A IL4 IL6 TNF
23
Show member pathways
12.49 CRP IFNG IL2 IL4 IL6 SAA1
24
Show member pathways
12.43 CXCL8 IFNG IL6 TLR4 TNF
25
Show member pathways
12.4 IFNG IL10 IL4 TLR4 TNF
26 12.4 IFNG IL10 IL18 IL6 TLR4 TNF
27 12.39 IL2 IL2RA IL6 TNF
28
Show member pathways
12.37 CXCL8 IL18 IL1RN IL6 TNF
29
Show member pathways
12.35 CXCL8 IFNG IL4 IL6 TLR4 TNF
30 12.33 CXCL8 IL10 IL1RN IL6 TNF
31
Show member pathways
12.32 CXCL8 IL6 TLR4 TNF
32
Show member pathways
12.28 IL10 IL2 IL6 TNF
33 12.26 IFNG IL6 TLR4 TNF
34
Show member pathways
12.23 CXCL8 IFNG IL10 IL17A IL18 IL2
35
Show member pathways
12.21 IFNG IL4 IL6 TLR4 TNF
36 12.2 CXCL8 IFNG IL2 IL4 IL6 TLR4
37
Show member pathways
12.2 CXCL8 IFNG IL10 IL17A IL18 IL2
38 12.17 IFNG IL10 IL2 IL2RA IL4 IL6
39
Show member pathways
12.15 IFNG IL18 IL2 IL2RA IL4
40
Show member pathways
12.15 IFNG IL10 IL17A IL18 IL2 IL6
41 12.06 CXCL8 IFNG IL10 IL6 TLR4 TNF
42 12.06 CXCL8 IL10 IL17A IL18 IL4 IL6
43 12.05 IFNG IL10 IL2 IL2RA IL6
44 12.02 IL2RA IL4 IL6 TNF
45 12.01 CXCL8 IFNG IL18 IL6 TLR4
46 12 CXCL8 IL18 IL2 TLR4
47
Show member pathways
12 CXCL8 IL17A IL6 TLR4
48 12 CXCL8 IFNG IL17A IL18 IL6 TLR4
49 11.99 CXCL8 IFNG IL2 IL4 IL6
50 11.96 CXCL8 IFNG IL6

GO Terms for Brucellosis

Cellular components related to Brucellosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 CRP CXCL8 IFNG IL10 IL17A IL18
2 extracellular space GO:0005615 9.4 CRP CXCL8 IFNG IL10 IL17A IL18

Biological processes related to Brucellosis according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.97 CXCL8 IFNG IL10 IL17A IL18 IL1RN
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.96 IL18 IL6 TLR4 TNF
3 regulation of signaling receptor activity GO:0010469 9.96 CXCL8 IFNG IL10 IL17A IL18 IL1RN
4 positive regulation of DNA-binding transcription factor activity GO:0051091 9.92 IL10 IL6 TNF
5 positive regulation of gene expression GO:0010628 9.92 CRP IFNG IL18 IL4 IL6 SLC11A1
6 defense response to Gram-positive bacterium GO:0050830 9.91 CRP IL6 TNF
7 defense response to Gram-negative bacterium GO:0050829 9.89 IL6 SLC11A1 TLR4
8 neutrophil chemotaxis GO:0030593 9.89 CXCL8 IL1RN SAA1
9 positive regulation of JNK cascade GO:0046330 9.89 IL1RN TLR4 TNF
10 positive regulation of inflammatory response GO:0050729 9.88 IL18 IL2 TLR4 TNF
11 negative regulation of inflammatory response GO:0050728 9.88 IL10 IL2 IL2RA MEFV SAA1
12 cellular response to lipopolysaccharide GO:0071222 9.88 CXCL8 IL10 IL1RN IL6 TLR4 TNF
13 humoral immune response GO:0006959 9.87 IFNG IL6 TNF
14 response to glucocorticoid GO:0051384 9.87 IL10 IL1RN IL6 TNF
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.86 IL18 IL6 TNF
16 positive regulation of T cell proliferation GO:0042102 9.86 IL2 IL2RA IL4 IL6
17 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.85 IL18 TLR4 TNF
18 positive regulation of interleukin-6 production GO:0032755 9.85 IL1RN IL6 TLR4 TNF
19 positive regulation of nitric oxide biosynthetic process GO:0045429 9.84 IFNG TLR4 TNF
20 positive regulation of B cell proliferation GO:0030890 9.83 IL2 IL4 TLR4
21 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 IFNG IL18 IL2 IL4 IL6
22 acute-phase response GO:0006953 9.81 CRP IL6 SAA1
23 lipopolysaccharide-mediated signaling pathway GO:0031663 9.81 IL18 TLR4 TNF
24 negative regulation of interleukin-6 production GO:0032715 9.8 IL10 TLR4 TNF
25 positive regulation of cytokine secretion GO:0050715 9.79 IL10 SAA1 TNF
26 positive regulation of activated T cell proliferation GO:0042104 9.79 IL18 IL2 IL2RA
27 positive regulation of osteoclast differentiation GO:0045672 9.78 IFNG IL17A TNF
28 positive regulation of chemokine production GO:0032722 9.77 IL6 TLR4 TNF
29 positive regulation of T cell differentiation GO:0045582 9.77 IL2 IL2RA IL4
30 positive regulation of interferon-gamma production GO:0032729 9.77 IL18 IL2 SLC11A1 TLR4 TNF
31 regulation of regulatory T cell differentiation GO:0045589 9.75 IFNG IL2 IL2RA
32 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.74 IFNG TNF
33 negative regulation of growth of symbiont in host GO:0044130 9.74 IL10 TNF
34 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.74 IL10 TNF
35 positive regulation of interleukin-17 production GO:0032740 9.74 IL18 IL2
36 regulation of protein secretion GO:0050708 9.74 SAA1 TNF
37 interferon-gamma production GO:0032609 9.73 IL18 TLR4
38 negative regulation of interleukin-12 production GO:0032695 9.73 IL10 MEFV
39 negative regulation of interleukin-17 production GO:0032700 9.73 IFNG TLR4
40 positive regulation of immunoglobulin secretion GO:0051024 9.73 IL2 IL6
41 response to molecule of bacterial origin GO:0002237 9.73 CXCL8 IL10
42 interleukin-2-mediated signaling pathway GO:0038110 9.72 IL2 IL2RA
43 macrophage activation GO:0042116 9.72 SLC11A1 TLR4
44 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.72 IL10 IL1RN
45 neutrophil activation GO:0042119 9.72 CXCL8 IL18
46 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.71 TLR4 TNF
47 positive regulation of isotype switching to IgG isotypes GO:0048304 9.71 IL2 IL4
48 negative regulation of lipid storage GO:0010888 9.71 CRP IL6 TNF
49 T-helper 1 type immune response GO:0042088 9.7 IL18 TLR4
50 endothelial cell apoptotic process GO:0072577 9.7 IL10 TNF

Molecular functions related to Brucellosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.32 CXCL8 IFNG IL10 IL17A IL18 IL1RN
2 growth factor activity GO:0008083 9.26 IL10 IL2 IL4 IL6
3 protein binding GO:0005515 10 CRP CXCL8 IFNG IL10 IL17A IL18

Sources for Brucellosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO